Johnson & Johnson’s $5 Billion INLEXZO Bet: What Will Happen If SunRISe-3 Delivers in 2027

Key Takeaways for Johnson & Johnson Stock as of June 2026

• Analysts rate Johnson & Johnson stock 10 buys, 5 outperforms, 7 holds, 1 underperform, and 1 sell with a mean target of $258, implying around 1% upside from the current price of $255.
• TIKR’s mid-case model values Johnson & Johnson at around $333 by December 2030, implying around 31% total return, or roughly 6% annualized over the next 4.5 years.
• Johnson & Johnson stock looks undervalued relative to its true growth trajectory, with revenue growth ex-STELARA running at around 17% operationally in Q1 2026 while consensus estimates price in only 5–8% going forward.
• ICOTYDE, J&J’s first-line oral psoriasis therapy, reached roughly 4,500 prescribers in under three months from launch, before any direct-to-consumer advertising campaign began.

See JNJ’s full financial data, valuation model, and analyst price targets on TIKR for free →

Johnson & Johnson Stock Gains Ground as New Launch Portfolio Drives Revenue Gap the Street Has Not Priced In

Johnson & Johnson (JNJ) delivered $24.1 billion in Q1 2026 revenue, up roughly 10% year-over-year, as new product launches accelerated growth against a stiff headwind from STELARA biosimilar competition, which dragged Innovative Medicine segment growth down by around 920 basis points.

Excluding STELARA, the Innovative Medicine division grew at roughly 17% operationally in the U.S. during Q1, the figure management has cited as the truer signal of portfolio velocity.

DARZALEX, the multiple myeloma backbone therapy, reached $4 billion in quarterly sales and grew nearly 18% year-over-year, driven by share gains of around 6 points across all therapy lines and nearly 12 points in frontline settings.

ICOTYDE, the first targeted IL-23 oral peptide approved for psoriasis, launched the same day it received FDA clearance in March 2026, with the first patient on treatment within 24 hours.

Tom Cavanaugh, Group Company Chairman of North American Innovative Medicine, told Goldman Sachs at the 47th Annual Global Healthcare Conference in June 2026: “If you think about a population, let’s take psoriasis, you have roughly 3 million to 5 million patients suffering from moderate to severe psoriasis. 75% of them are cycling through therapies or not on advanced systemic treatment.”

The prescriber base reached roughly 4,500 unique writers in under three months, with around 60% of early patients being systemic-treatment naive and no direct-to-consumer campaign yet running.

INLEXZO, the intravesical drug-releasing system for BCG-unresponsive non-muscle invasive bladder cancer, posted sales slightly above $30 million in Q1, then logged over 50% growth in new patient insertions in the first week after J-code reimbursement approval on April 1, rising to nearly 90% in week two.

Its current BCG-unresponsive indication addresses roughly 3,000 patients; two expansion trials, SunRISe-5 (BCG-exposed, roughly 15,000 patients) and SunRISe-3 (BCG-naive, roughly 40,000 to 50,000 patients), are expected to read out in 2026 and 2027.

RYBREVANT plus LAZCLUZE delivered $257 million in Q1 revenue, up roughly 81% year-over-year, and currently treats around 1 in 4 eligible EGFR-mutated lung cancer patients globally, with head-and-neck data at ASCO 2026 showing a 42% confirmed response rate.

J&J raised full-year 2026 guidance to $100.2 billion at the operational midpoint and maintained guidance for adjusted pretax operating margin improvement of at least 50 basis points.

Track J&J’s revenue growth and new launch metrics quarter by quarter on TIKR for free →

Analysts Rate Johnson & Johnson Stock Near Consensus on Price But Below Management’s Growth Trajectory

JNJ stock carries 10 buy ratings, 5 outperforms, 7 holds, 1 underperform, and 1 sell from 24 analysts as of June 26, 2026.

The mean analyst price target sits at around $258, implying around 1% upside from the current price of $255.

Leerink Partners upgraded Johnson & Johnson stock to outperform in May 2026 with a raised target of $265, flagging new drug momentum as the driver and calling ICOTYDE, INLEXZO, and RYBREVANT as the key underappreciated growth levers.

The range of analyst targets runs from $190 to $285, a spread that reflects genuine disagreement over how fast the new launch portfolio can compound.

Wall Street Expects Johnson & Johnson Stock Revenue to Accelerate Through 2026 and 2027

Consensus revenue estimates for Johnson & Johnson sit at around $25 billion for Q2 2026, up roughly 5% year-over-year, with Q3 2026 expected at around $25.3 billion, also around 5% growth.

Q4 2026 estimates rise to around $26.5 billion, reflecting a roughly 8% year-over-year gain, partially boosted by the 53rd-week calendar benefit that management flagged in its full-year guidance.

Analysts project Q1 2027 revenue at around $25.4 billion and Q2 2027 at around $26.5 billion, both running at roughly 6% year-over-year growth, which management has described as below the true ex-STELARA trajectory already being achieved.

The key threshold to watch is whether ICOTYDE and INLEXZO, which together have been projected by management to reach $5 billion-plus each in peak annual sales, begin to move consensus estimates materially higher as launch data accumulates through the second half of 2026.

TIKR’s $333 Target on JNJ Stock Holds if New Launches Compound as the Data Suggests

TIKR’s mid-case model values Johnson & Johnson stock at around $333 by December 2030, implying around 31% total return from the current price of $255, or roughly 6% annualized over the next 4.5 years.

That return positions Johnson & Johnson stock as a steady compounder, consistent with a large-cap healthcare business where the upside comes from duration and launch compounding rather than multiple expansion.

The path to $333 runs through the same dynamics already visible in Q1: ICOTYDE scaling into psoriatic arthritis and IBD, INLEXZO’s population expanding from roughly 3,000 BCG-unresponsive patients toward a 50,000-patient addressable market, and RYBREVANT adding head-and-neck and colorectal indications to its lung cancer base, all compounding against a Street consensus that still prices in only mid-single-digit revenue growth.

Wall Street’s best ideas don’t stay hidden for long. Catch analyst upgrades, earnings beats, and revenue surprises on thousands of stocks the moment they happen with TIKR for free →

Should You Invest in Johnson & Johnson?

The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.

Pull up JNJ stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.

You can build a free watchlist to track Johnson & Johnson alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.

Access Professional Tools to Analyze JNJ stock on TIKR for Free →